Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)

May 27, 2026 updated by: Albireo, an Ipsen Company

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in children with biliary atresia who have undergone a Kasai hepatoportoenterostomy.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Up to 70 sites will be initiated for this study in North America, Europe, Middle East, and Asia Pacific.

Study Type

Interventional

Enrollment (Actual)

254

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Parkville, Australia, 3052
        • Royal Children's Hospital
      • Sydney, Australia
        • The Children´s Hospital at Westmead
    • South Australia
      • North Adelaide, South Australia, Australia
        • Women's and Children's Hospital (Women's and Children's Health Network, Incorporated.)
  • Belgium
      • Brussels, Belgium
        • Cliniques universitaires Saint-Luc
      • Ghent, Belgium
        • UZ Gent
  • Canada
      • Montreal, Canada
        • CHU Sainte-Justine
      • Toronto, Canada
        • The Hospital for Sick Children
  • China
      • Shanghai, China
        • Children's Hospital of Fudan University
    • Guangdong
      • Guangzhou, Guangdong, China
        • Guangzhou Women and Children's Medical Center
  • France
      • Bron, France
        • Hôpital Femme Mère Enfant
      • Le Kremlin-Bicêtre, France
        • Bicêtre Hospital
      • Lille, France
        • Jeanne de Flandre Hospital
      • Paris, France
        • Necker University Hospital - Enfants malades
  • Germany
      • Berlin, Germany
        • Charite - Universitatsmedizin Berlin
      • Hamburg, Germany
        • University Medical Center Hamburg-Eppendorf UKE
      • Hanover, Germany
        • Hannover Medical School
      • Munich, Germany
        • Dr von Hauner Children´s Hospital LMU
      • Tübingen, Germany
        • University Children´s Hospital Tuebingen
  • Hungary
      • Budapest, Hungary
        • Semmelweis Egyetem I.sz Gyermekgyógyászati Klinika
  • Israel
      • Jerusalem, Israel
        • Shaare Zedek Medical Center
      • Petah Tikva, Israel
        • Schneider Children´s Medical Center of Israel
  • Italy
      • Bergamo, Italy
        • Asst Papa Giovanni Xxiii
      • Florence, Italy
        • Meyer Children´s University Hospital
      • Padova, Italy
        • University Hospital of Padova
      • Palermo, Italy
        • ISMETT - Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione
      • Roma, Italy
        • Ospedale Pediatrico Bambino Gesù
      • Turin, Italy
        • Regina Margherita Children´s Hospital
  • Malaysia
      • Kota Bharu, Malaysia
        • Hospital Raja Perempuan Zainab II
      • Kuala Lumpur, Malaysia
        • University of Malaya Medical Centre
  • Netherlands
      • Groningen, Netherlands
        • University Medical Center Groningen
  • New Zealand
      • Auckland, New Zealand
        • Starship Child Health
  • Poland
      • Warsaw, Poland
        • Instytut Pomnik-Centrum Zdrowia Dziecka
  • South Korea
      • Seoul, South Korea
        • Samsung Medical Center
      • Seoul, South Korea
        • Seoul National University Children's Hospital
  • Spain
      • Barcelona, Spain
        • Hospital Universitari Vall d'Hebron
  • Taiwan
      • Taipei, Taiwan
        • National Taiwan University Hospital
      • Taipei, Taiwan
        • Taipei Veterans General Hospital
  • Turkey (Türkiye)
      • Ankara, Turkey (Türkiye)
        • Hacettepe University Ihsan Dogramaci Childrens Hospital
      • Antalya, Turkey (Türkiye)
        • Akdeniz University Medical Faculty
      • Istanbul, Turkey (Türkiye)
        • Istanbul University, Istanbul Medical Faculty
  • United Kingdom
      • Birmingham, United Kingdom
        • Birmingham Women´s and Children´s Hospital
      • Leeds, United Kingdom
        • Leeds General Infirmary
  • United States
    • California
      • Los Angeles, California, United States, 90027
        • Children's Hospital Los Angeles
      • Palo Alto, California, United States, 94304
        • Stanford Children's Health
      • San Diego, California, United States, 92123
        • Rady Children's Hospital
      • San Francisco, California, United States, 94158
        • UCSF Benioff Children's Hospital San Francisco
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Children's Hospital Colorado
    • Delaware
      • Wilmington, Delaware, United States, 19803
        • Nemours/Alfred I. duPont Hospital for Children
    • District of Columbia
      • Washington D.C., District of Columbia, United States, 20010
        • Children's National Medical Center
    • Florida
      • Miami, Florida, United States, 33146
        • University of Miami
    • Georgia
      • Atlanta, Georgia, United States, 30322
        • Children's Healthcare of Atlanta - Emory University School of Medicine
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Ann & Robert H. Lurie Children's Hospital
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Indiana University School of Medicine
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins Children's Center
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • University of Michigan Children's Hospital
    • Missouri
      • Kansas City, Missouri, United States, 64108
        • Children's Mercy Hospital
      • St Louis, Missouri, United States, 63110
        • Washington University in St. Louis
    • New York
      • New York, New York, United States, 10029
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, United States, 10032
        • NewYork-Presbyterian Morgan Stanley Children's Hospital
      • New York, New York, United States, 10016
        • NYU Grossman school of Medicine
      • The Bronx, New York, United States, 10467
        • The Children's Hospital at Montefiore
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Duke Central Tower
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19104
        • The Children´s Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15224
        • UPMC Children's Hospital of Pittsburgh
    • Texas
      • Dallas, Texas, United States, 75390
        • UT southwestern Medical Center
    • Utah
      • Salt Lake City, Utah, United States, 84113
        • University of Utah
    • Washington
      • Seattle, Washington, United States, 98105
        • Seattle Children's Hospital
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53226
        • Medical College of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 3 years (Child)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • A male or female patient with a clinical diagnosis of BA
  • Age at Kasai HPE ≤90 days
  • Eligible to start study treatment within 3 weeks post-Kasai HPE

Key Exclusion Criteria:

  • Patients with intractable ascites
  • Ileal resection surgery
  • ALT ≥10× upper limit of normal (ULN) at screening
  • Patients reliant only on total parenteral nutrition, or not able to take study medication orally, at randomization
  • Acute ascending cholangitis (patients may be randomized after resolution of acute ascending cholangitis)
  • Choledochal cystic disease
  • INR >1.6 (the patient may be treated with Vitamin K intravenously; sample may be redrawn and if INR is ≤1.6 at resampling the patient may be randomized)
  • Any other conditions or abnormalities, including congenital abnormalities, major cardiac surgery, hepatic, biliary, or GI disease which, in the opinion of the Investigator or Medical Monitor, may compromise the safety of the patient, the integrity of study results, or patient compliance with study requirements
  • Weight <3.5kg at randomization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Odevixibat (A4250)
Capsules for oral administration once daily for 104 weeks.
Drug: Odevixibat
Odevixibat is a small molecule and selective inhibitor of IBAT.
Placebo Comparator: Placebo
Capsules for oral administration (to match active) once daily for 104 weeks.
Drug: Placebo
Placebo identical in appearance to experimental drug (odevixibat).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Time from randomization to first occurrence of liver transplant, or death
Time Frame: From baseline to Week 104
From baseline to Week 104

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to onset of any sentinel events
Time Frame: From baseline to Week 104
Time to onset of any sentinel events
From baseline to Week 104
Time to pediatric end-stage liver disease (PELD) score >15
Time Frame: From baseline to Week 104
Time to pediatric end-stage liver disease (PELD) score >15
From baseline to Week 104
Total bilirubin levels
Time Frame: From baseline to Weeks 13, 26, 52 and 104
Total bilirubin level after 13, 26, 52, and 104 weeks of study treatment
From baseline to Weeks 13, 26, 52 and 104
Serum bile acid levels
Time Frame: From baseline to Weeks 13, 26, 52 and 104
Serum bile acid level after 13, 26, 52, and 104 weeks of study treatment
From baseline to Weeks 13, 26, 52 and 104
Percentage of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From baseline to Week 104
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
From baseline to Week 104
Percentage of participants with clinically significant changes in Physical Examination
Time Frame: From baseline to Week 104
Percentage of participants with clinically significant changes in physical examination findings will be reported. The clinical significance will be graded by the investigator.
From baseline to Week 104
Percentage of participants with clinically significant changes in Laboratory Parameters (blood chemistry, hematology and coagulation)
Time Frame: From baseline to Week 104
Percentage of participants with clinically significant change in laboratory parameters (blood chemistry, hematology and coagulation) will be reported. The clinical significance will be decided by the investigator.
From baseline to Week 104
Percentage of participants with clinically significant changes in Abdominal Ultrasound findings
Time Frame: From baseline to Week 26 and Week 104
Percentage of participants with clinically significant change in Abdominal Ultrasound findings will be reported. The clinical significance will be decided by the investigator.
From baseline to Week 26 and Week 104
Proportion of patients with liver transplant
Time Frame: From baseline to Week 104
Proportion of patients who are alive and have not undergone a liver transplant
From baseline to Week 104

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Albireo, an Ipsen Company

Investigators

  • Study Director: Ipsen Medical Director, Ipsen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2020

Primary Completion (Estimated)

June 22, 2026

Study Completion (Estimated)

June 22, 2026

Study Registration Dates

First Submitted

March 27, 2020

First Submitted That Met QC Criteria

April 3, 2020

First Posted (Actual)

April 7, 2020

Study Record Updates

Last Update Posted (Actual)

May 28, 2026

Last Update Submitted That Met QC Criteria

May 27, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • A4250-011
  • 2019-003807-37 (EudraCT Number)
  • 2024-512086-14-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD Sharing Time Frame

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD Sharing Access Criteria

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Biliary Atresia

Clinical Trials on Odevixibat

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe